Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosis

American Journal of Hematology

Volumn 87, Issue 11, 2012, Pages 1003-1005

  Vaidya, Rakhee ^a   Gangat, Naseema ^a   Jimma, Thitina ^a   Finke, Christy M ^a   Lasho, Terra L ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CXCL9 CHEMOKINE; CYTOKINE; EOTAXIN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGE; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; POLYCYTHEMIA VERA; PREDICTIVE VALUE OF TESTS; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84867918380     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23295     Document Type: Article

References (14)

1. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005; 23: 8520-8530.
2. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
3. Pardanani A, Finke C, Lasho TL, et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 2011; 26: 693-699.
4. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol Official J Am Soc Clin Oncol 2011; 29: 392-397.
5. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
6. Kornblau SM, McCue D, Singh N, et al. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010; 116: 4251-4261.
7. Pardanani A, Begna K, Finke C, et al. Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis. Am J Hematol 2011; 86: 343-345.
8. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
9. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937-951.
10. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post- essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437-438.
11. Schall TJ, Bacon K, Camp RD, et al. Human macrophage inflammatory protein alpha (MIP-1α) and MIP-1β chemokines attract distinct populations of lymphocytes. J Exp Med 1993; 177: 1821-1826.
12. Burger JA, Quiroga MP, Hartmann E, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009; 113: 3050-3058.
13. Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
14. Sivina M, Hartmann E, Kipps TJ, et al. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 2011; 117: 1662-1669.